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Abstract
Biomarkers can be used to assess smoking behaviour more accurately and objectively
than self-report. This study assessed the association between cotinine (a biomarker of
smoke exposure) and later e-cigarette use among a population who were unexposed to
e-cigarettes in youth. Young people in the Avon Longitudinal Study of Parents and Chil-
dren took part in the study. We observed associations between cotinine at 15 years
(measured between 2006 and 2008 before the wide availability of e-cigarettes) and self-
reported ever use of e-cigarettes at 22 (measured between 2014 and 2015 when e-ciga-
rettes were widely available) using logistic regression. A range of potential confounders
were adjusted for (age, sex, body mass index, alcohol use and passive smoke expo-
sure). Additionally, we adjusted for the young people’s self-reported smoking status/his-
tory to explore potential misreporting and measurement error. In a sample of N = 1,194
young people, cotinine levels consistent with active smoking at 15 years were associ-
ated with increased odds of e-cigarette ever use at 22 years (Odds Ratio [OR] = 7.24,
95% CI 3.29 to 15.93) even when self-reported active smoking status at age 16 (OR =
3.14, 95% CI 1.32 to 7.48) and latent classes of smoking behaviour from 14 to 16 (OR =
2.70, 95% CI 0.98 to 7.44) were included in the model. Cotinine levels consistent with
smoking in adolescence were strongly associated with increased odds of later e-ciga-
rette use, even after adjusting for reported smoking behaviour at age 16 and smoking
transitions from 14 to 16.
Introduction
There are an estimated 3.2 million e-cigarette users (also known as vapers) in the UK [1]. In
2015, just under 5% of 16 to 24 year olds were estimated to be current e-cigarette users in the
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Data Availability Statement: Data cannot be
shared publicly because the ALSPAC Ethics and
Law Committee and the Local Research Ethics
Health Survey for England [2]. Evidence suggests that e-cigarettes could be considerably less
harmful than smoking [3] and that they can be effective in aiding smoking cessation [4]. Fur-
thermore, frequent e-cigarette use among tobacco-naïve young people appears to be rare [5].
However, concerns have been raised about the use of e-cigarettes by non-smokers and given
the potential harms of e-cigarette use (e.g., adverse pulmonary [6] and cardiovascular [7]
effects), further investigation of the potential risk factors for e-cigarette use is warranted.
Previous research exploring associations between tobacco smoking and e-cigarette use
among young people have generally relied on self-report data in cross-sectional surveys and
longitudinal cohorts [8]. Self-reports of smoking behaviour have been shown to be less accu-
rate than objective measures such as cotinine, which can increase detection of current smokers
compared to self-report [9]. The high potential for measurement error when using self-reports
of smoking means it is difficult to draw conclusions regarding the chronology of events i.e.,
that smoking preceded e-cigarette use or vice versa. Thus, there is limited objective evidence
for whether smoking is associated with later e-cigarette use among young people or whether e-
cigarette use is associated with later smoking among young people.
Cotinine is a direct metabolite of nicotine which can be used to assess recent smoke expo-
sure (half-life of approximately 10–27 hours) [10]. It may also serve as an indicator for misre-
porting of smoking by providing biological evidence that smoking has occurred when
individuals report that they have not smoked [11–13]. For example, one study reported that
among self-reported non-smokers, 6% were misclassified and according to their cotinine levels
had in fact recently smoked [12]. Therefore, cotinine could provide less biased evidence of
association between smoking behaviour and later e-cigarette use.
To our knowledge, there have been no studies assessing the association of cotinine mea-
surement in adolescence with e-cigarette use in early adulthood. We therefore examined the
associations of cotinine with later ever e-cigarette use using biochemical verification of smok-
ing status to further explore previous findings suggesting self-reported smoking is associated
with later e-cigarette use. We also investigated any residual associations after accounting for
self-reported smoking, in order to explore whether objectively assessed smoking is associated
with e-cigarette use over and above self-reported smoking (which may be subject to
misreporting).
Materials and methods
Sample
The study sample consisted of young people from the Avon Longitudinal Study of Parents and
Children (ALSPAC) [14, 15]. A total of 15,454 pregnant women resident in Avon, UK with
expected dates of delivery between 1st April 1991 to 31st December 1992 were recruited, result-
ing in 15,589 fetuses. Most of these women were recruited whilst pregnant; however, 913
women who had delivery dates within this time frame were recruited in later phases when the
children were roughly 7 years and older. The phases of enrolment are described in more detail
in the cohort profile update [16]. Of this total sample, 14,901 were alive at 1 year of age (see Fig
1). The study website contains details of all the data that is available through a fully searchable
data dictionary: http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/. Ethics
approval for the study was obtained from the ALSPAC Ethics and Law Committee and the
Local Research Ethics Committees. Informed consent for the use of data collected via ques-
tionnaires and clinics was obtained from participants following the recommendations of the
ALSPAC Ethics and Law Committee at the time. Fig 1 shows the process from recruitment to
the final sample selection.
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Cotinine as a biomarker for predicting smoke exposure in adolescence
Cotinine is a commonly used biomarker for assessing nicotine consumption [17]. In this
study, cotinine levels were measured from blood samples taken in a clinic assessment of the
ALSPAC young people when they were 15 years old (between 2006 and 2008). Cotinine was
assayed from ethylenediaminetetraacetic acid serum plasma samples which had been stored at
−80˚C and allowed to thaw at room temperature before use. Cotinine was measured using the
Cozart Cotinine Enzyme Immunoassay (Concateno UK, Abingdon) serum kit (M155B1). All
samples, calibrators, and controls were brought to room temperature before use and were run
in duplicate. Where required, samples were diluted using cotinine-free serum (fetal calf
serum). Absorbance was measured spectrophotometrically at a wavelength of 450nm.
A presence of 10 ng/ml (nanograms per millilitre of serum) or more of cotinine in the blood
stream is indicative of being an active smoker [18]. Levels below this but above 0 ng/ml would
indicate some exposure to tobacco smoke and levels of 0 ng/ml would indicate no exposure. The
young adults were categorised into three groups (0 ng/ml, no smoke exposure; between 0 and 10
ng/ml, passive smoke exposure; 10+ ng/ml, active smoking). Cotinine variables were grouped due
to the non-linear association previously found between cotinine and smoke exposure [11, 19].
Self-reported smoking in adolescence and early adulthood
Smoking status was assessed in adolescence (16 years) and in early adulthood (22 years). At 16
and 22 years, young people self-reported whether they had ever smoked a cigarette (yes/no)
and the number of cigarettes they had ever smoked (less than 5, 5–19, 20–49, 100 plus). For
analysis, the number of cigarettes ever smoked was recoded to include a 0 cigarettes category
based on their response to ever smoking (“No” = 0). The frequency at which the young person
smoked at age 16 was also measured (did not smoke, smoked once ever, used to smoke but did
not at time of measure, smoked less than once a week, smoked 1–6 cigarettes a week, smoked
Fig 1. Flow chart depicting the process of data inclusion in the analysis of the associations between cotinine samples at ages 15–17
and ever e-cigarette use at age 22.
https://doi.org/10.1371/journal.pone.0235629.g001
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6+ cigarettes a week, smoked daily). This variable was also recoded into a binary variable for
active (weekly/daily smoking) vs not active (all other responses) smoking. At 22 years, young
people additionally self-reported whether they had smoked in the past 30 days (yes/no).
Due to the limitations of using secondary data we were unable to acquire measures of self-
reported exposure at the same time as measures of cotinine. Self-reported measures were col-
lected via questionnaire an average of 15 months after cotinine, which was measured at a clinic
session. Time between the measures ranged between 0 and 29 months apart. To account for
the potential variability in smoking behaviour over time in youth, Longitudinal Latent Class
Analysis (LLCA) was also performed using Mplus v8 [20] to derive smoking classes based on a
four-category ordinal variable with categories ‘none’, ‘less than weekly’, ‘weekly’ and ‘daily’
smoking from three questionnaire time points (14, 15 and 16 years), as has been described pre-
viously [21]. A 4-class model was selected for the repeated measures of smoking frequency,
comprising smoking behaviour patterns that we refer to as never-smokers (84%), experiment-
ers (6%), late onset regular smokers (9%) and early onset regular smokers (2%). These classes
are consistent with those derived previously by Heron et al. [21], where non-smokers reported
very little or no smoking, experimenters smoked infrequently (monthly), late-onset regular
smokers were individuals who began smoking by age 14 and were mostly daily smokers by age
16 and early-onset regular smokers were mostly daily smokers by age 14. Given the very high
entropy of the 4-class model, individuals were assigned to the class for which they had the
highest probability of class membership (modal class assignment) and the latent classes were
used as an observed categorical exposure in further analyses.
E-cigarette use in adulthood
E-cigarette use was determined by self-report questionnaire during 2014–2015 when the
young people were 22 years old. Study data at 22 years were collected and managed using
REDCap electronic data capture tools hosted at the University of Bristol [22]. Participants
were given a yes/no option to the question: “have you ever used/smoked/vaped an electronic
cigarette?” Additional information was collected regarding current (past 30-day) use of e-ciga-
rettes but these data were not used as the main outcome due to sample size constraints.
Covariates
A variety of covariates were included that could impact on the association between biomarkers
of smoking and later e-cigarette use; sex (male/female), age at the time of questionnaire (quar-
tiles younger to older), parental education (at 32 weeks of gestation; Degree, A-level, O-level,
less than O-level; defined in S1 File), body mass index (BMI at 15 years old), parental social class
(at 18 weeks of gestation; manual, non-manual), passive smoke exposure (maternal smoking at
12 years old) and alcohol use (whether the young person had drunk a whole alcoholic beverage
in the past 30 days at 15 years old). Self-reported ever cannabis use (at 15 years) was included as
a covariate in supplementary analyses. Self-reported smoke exposure (whether the young person
had ever smoked, the number of cigarettes smoked, whether they were active smokers at 16
years, and latent classes of smoking transitions between the ages of 14, 15 and 16 [latent classes:
never smokers, experimenters, late onset regular smokers, early onset regular smokers; within
class probabilities are shown in S1–S4 Figs]) was also included in further models.
Statistical analyses
Analyses were completed in Stata SE 15.1 (Stata Corp LP, College Station, TX USA). Differ-
ences in sociodemographic characteristics between the young people who had never used an
e-cigarette versus those who had ever used an e-cigarette by 22 years were assessed using a chi
PLOS ONE Added value of biomarkers compared with self-reported smoking in predicting future e-cigarette use
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square test for categorical variables and t-test for continuous variables. Associations between
cotinine at age 15 and ever e-cigarette use at age 22 years were assessed in a series of logistic
regressions. Cases with missing data (exposure, outcome or covariate data) were not included
in the analyses.
Analysis of cotinine data was performed on both categorised (main text) and continuous
(supplementary) data. Emphasis has been placed on the analysis of the categorical data for two
reasons: 1) the continuous cotinine data were positively skewed and attempts at transforming
the data did not sufficiently address the issue; and 2) non-linear relationships between cotinine
and smoke exposure may mean that continuous models might not be informative [11, 19].
Three models were used to analyse the associations between cotinine and later e-cigarette
use before adjusting for self-reported smoking; the basic model (Model 1) adjusted for sex and
age at cotinine sample collection; Model 2 additionally adjusted for BMI, socio-economic posi-
tion (social class, maternal and paternal education) and alcohol use; Model 3 additionally
adjusted for passive smoke exposure (maternal smoking) at 12 years. A further four models
were used to analyse the association while adjusting for self-reported smoking. These further
models were as Model 3 and additionally adjusted for ever smoking at age 16 (Model 4a),
number of cigarettes smoked in their lifetime at 16 (Model 4b), active smoking (daily/weekly)
at age 16 (Model 4c), or smoking transitions from age 14 to 16 (Model 4d). On average, the
time between the measure of cotinine at 15 years and the self-reported measure of smoking
status at 16 years was 15 months, with a range of 0 to 29 months. Given the short half-life of
cotinine and the potential variability in smoking behaviour over time in youth, Models 4a-4c
also adjusted for the time (months) between cotinine measure and self-report at 16. Any asso-
ciations observed in Models 1–3 were expected to attenuate to the null in Models 4a-4d in the
absence of measurement error in the self-report.
Model fit was assessed using likelihood ratio tests in which the models including and
excluding the exposure (cotinine) were compared. Substantial differences between the two
models indicate that the model including cotinine was more predictive of the outcome (i.e.,
the model was a good fit).
A sensitivity analysis was conducted to explore whether time between measures of cotinine
and self-reported smoking behaviour may have influenced the results. We explored whether
restricting the analysis to those with a time gap of 18 months or less between the smoking mea-
sures would affect the interpretation of the results.
Results
Characteristics of participants
At 22 years, the question regarding ever e-cigarette use was completed by 3,965 participants, 955
(24%) of whom responded that they had previously used/smoked/vaped an e-cigarette. Of those
who had ever used an e-cigarette, 111 (12%) stated that they were currently using one. Table 1
contains the participants’ sociodemographic data stratified by their use of e-cigarettes (ever/
never) at 22 years. There was strong evidence for differences between groups in terms of sex,
BMI, alcohol use and smoking behaviour (at 16 and 22 years). Among never users of e-cigarettes
at 22 years, 37% had ever smoked at 16 and 48% had smoked at 22 years (self-reported). For ever
e-cigarette users at 22 years, 74% had ever smoked at age 16 and 95% had ever smoked at age 22
(self-reported). There was also weak evidence that maternal education differed between groups.
Cotinine levels and e-cigarette ever use at 22 years
The main results for the associations between cotinine and e-cigarette ever use can be found in
Table 2. Levels of cotinine indicative of passive smoke exposure at 15 years were not clearly
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associated with ever e-cigarette use at 22 years (p> .28). Levels of cotinine indicative of active
smoking at 15 years were associated with a 10-fold increase in the odds of having ever used e-
cigarettes at 22, compared with those with no smoke exposure (basic adjusted OR 10.47, 95%
CI 4.88 to 22.46, p< .001). This positive association remained following additional adjust-
ment, although was weakened when adjusting for self-reported smoking behaviour at age 16
(ever smoking, OR 5.00, 95% CI 2.25 to 11.14, p< .001; number of cigarettes smoked, OR
2.35, 95% CI 0.98 to 5.62, p = .055; active [weekly/daily] smoking, OR 3.15, 95% CI 1.32 to
7.48, p = .010; and smoking transitions, OR 2.70, 95% CI 0.98, 7.44, p = .054). Including cotin-
ine in the model improved the model fit for Models 1, 2, 3, 4a and 4c (p< .001), but not 4b
Table 1. Sociodemographic profile of the sample population.
Variable Never used an e-cigarette at 22 years
(n = 3,010)
Had ever used an e-cigarette by 22 years
(n = 955)
n/Mean %/SD n/Mean SD/% p-value
Male 1000 33% 367 38% .003
Age in months at cotinine measure (15 years)� 185 4 185 4 .42
BMI at 15 years� 21 3 22 4 .001
Social class (non-manual) 2,314 86% 713 84% .24
Maternal education .024
Degree or above 584 21% 147 17%
A level 769 28% 248 29%
O level 929 34% 300 35%
Less than O level 459 17% 170 20%
Paternal education .12
Degree or above 767 29% 205 24%
A level 770 29% 250 30%
O level 554 21% 187 22%
Less than O level 599 22% 202 24%
Alcohol use in the past 30 days at 15 1,211 57% 476 76% < .001
Ever smoked at age 16 851 37% 481 74% < .001
Number of cigarettes smoked by age 16 < .001
0 1,472 64% 167 26%
Less than 5 403 17% 123 19%
5–19 154 7% 82 13%
20–49 95 4% 56 9%
50–99 66 3% 49 8%
100 or more 123 5% 170 26%
Active (daily/weekly) smoking at age 16 123 5% 188 29% < .001
Ever smoked at age 22 1,443 48% 908 95% < .001
Current smoker at age 22 412 14% 588 62% < .001
Number of cigarettes smoked by age 22 < .001
0 1,534 52% 46 5%
Less than 5 301 10% 40 4%
5–19 310 11% 64 7%
20–49 218 7% 57 6%
50–99 144 5% 59 6%
100 or more 444 15% 670 72%
Samples relate to the young people unless otherwise stated. P-values from chi square test for categorical variables and t-test for continuous variables.
�Mean and standard deviation (SD) are presented for these variables. All other variables display the number of participants (n) and percentage of the population.
https://doi.org/10.1371/journal.pone.0235629.t001
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(likelihood ratio = 3.87, p = .14) or 4d (likelihood ratio = 3.91, p = .14). The evidence of an
association was much weaker in the analysis of the continuous data (S1 Table). Including can-
nabis as a covariate further attenuated the association but some residual association was still
seen (S2 Table).
Self-reported smoking and potential misreporting
Although strong associations were seen between self-reported smoking behaviour and smok-
ing behaviour determined by cotinine (Table 3), discrepancies indicate that misreporting may
have occurred (Table 4). Only 56% of those who had cotinine levels indicative of being an
active smoker self-reported daily smoking. 19% of those indicated to be active smokers by
their cotinine levels reported that they were current non-smokers and 25% reported their
smoking behaviour as weekly or less. Conversely, only 36% of those who self-reported being
daily smokers also had cotinine levels indicating active smoking. Furthermore, e-cigarette use
at 22 years was more strongly associated with cotinine levels indicating active smoking (OR
adjusted for age and sex = 10.47, 95% CI 4.88 to 22.46, p< .001), than with self-reported active
daily/weekly smoking at 15 years (OR adjusted for age and sex = 7.77, 95% CI 5.09 to 11.85,
p< .001), albeit with overlapping confidence intervals (Table 5).
Transitions in smoking and ever e-cigarette use at 22 years
The association among the different latent classes of transitions in smoking between 14 and 16
years and e-cigarette use at 22 years (adjusting for all model 3 covariates, including cotinine)
are shown in Table 6. Experimenters and late onset regular smokers had increased odds of
ever using an e-cigarette at 22 years. There was no clear difference in odds of ever e-cigarette
use between early onset regular smokers and never smokers.
Sensitivity analyses
We next evaluated whether the discrepancies between self-reported smoking and cotinine lev-
els were due to the fact that cotinine measures were taken between 0 and 29 months after the
Table 2. Associations of cotinine at 15 years and ever use of e-cigarettes at 22 years (N = 1,194).
Model Cotinine
Passive (n = 797) Active (n = 36)
OR 95% CI p-value OR 95% CI p-value
1 1.19 0.87, 1.63 .28 10.47 4.88, 22.46 < .001
2 1.13 0.81, 1.56 .47 8.06 3.69, 17.61 < .001
3 1.10 0.80, 1.52 .56 7.24 3.29, 15.93 < .001
4a 1.15 0.82, 1.61 .42 5.00 2.25, 11.14 < .001
4b 1.07 0.76, 1.51 .71 2.35 0.98, 5.62 .055
4c 1.06 0.76, 1.48 .71 3.14 1.32, 7.48 .010
4d 1.05 0.75, 1.46 .79 2.70 0.98, 7.44 .054
Reference group = no exposure; OR = odds ratio; 95% CI = 95% confidence interval. Cotinine was treated as a categorical variable in these analyses. Passive exposure is
defined as levels exceeding 1 ng/ml in blood samples (up to 9 ng/ml). Active exposure is defined as cotinine levels exceeding 10 ng/ml in blood samples. The basic model
(model 1) was adjusted for age and sex. Model 2 was additionally adjusted for socioeconomic status, BMI and alcohol. Model 3 was additionally adjusted for passive
smoke exposure (maternal smoking at 12 years). Models 4a-4c were as model 3 and additionally adjusted for self-reported measures of smoking and the difference in
age between the self-report and cotinine measures. Model 4a adjusted for ever smoking at age 16. Model 4b alternatively adjusted for number of cigarettes smoked by
age 16. Model 4c alternatively adjusted for active smoking (daily/weekly) at age 16. Model 4d was as Model 3 and adjusted for classes of smoking transitions; early onset
regular smokers, late onset regular smokers, never smokers and experimenters categorised using data from 14 to 16.
https://doi.org/10.1371/journal.pone.0235629.t002
PLOS ONE Added value of biomarkers compared with self-reported smoking in predicting future e-cigarette use
PLOS ONE | https://doi.org/10.1371/journal.pone.0235629 July 14, 2020 7 / 15
16 year questionnaire on smoking behaviour in which smoking status was self-reported, and
therefore due to changing smoking habits in that time rather than misreporting. Although the
evidence of a residual association after adjusting for self-reported smoking status was weaker,
there was still some evidence of an association in the sensitivity analysis (S3 Table), indicating
that the residual association is not due to the time gap between the measures. The restriction
Table 3. Associations of cotinine and smoking behaviours in a series of logistic regressions.
Model 1 2 3
Smoking behaviour OR 95% CI p OR 95% CI p OR 95% CI p
Ever smoked a cigarette at age 16 (n = 1794)
No cotinine exposure (reference) 1.00 - - 1.00 - - 1.00 - -
Passive cotinine exposure 1.06 0.86, 1.30 .60 0.95 0.76, 1.19 .68 0.93 0.74, 1.17 .53
Active cotinine smoking 94.97 13.07, 689.89 < .001 70.29 9.55, 517.40 < .001 64.31 8.71, 475.06 < .001
Number of cigarettes smoked by age 16 (n = 1786)
No cotinine exposure (reference) 1.00 - - 1.00 - - 1.00 - -
Passive cotinine exposure 1.13 0.93, 1.38 .21 1.01 0.82, 1.24 .91 0.99 0.81, 1.22 .96
Active cotinine smoking 70.68 36.62, 136.43 < .001 53.46 27.20, 105.06 < .001 49.01 24.84, 96.73 < .001
Active (daily/weekly) smoking at age 16 (n = 1829)
No cotinine exposure (reference) 1.00 - - 1.00 - - 1.00 - -
Passive cotinine exposure 1.48 0.98, 2.23 .064 1.27 0.84, 1.94 .26 1.24 0.81, 1.89 .33
Active cotinine smoking 43.21 23.12, 80.77 < .001 32.34 16.94, 61.72 < .001 28.70 14.93, 55.18 < .001
Ever smoked a cigarette at age 22 (n = 1307)�
No cotinine exposure (reference) 1.00 - - 1.00 - - 1.00 - -
Passive cotinine exposure 1.12 0.88, 1.43 .35 1.07 0.83, 1.38 .62 1.05 0.81, 1.36 .72
Number of cigarettes smoked by age 22 (n = 1345)
No cotinine exposure (reference) 1.00 - - 1.00 - - 1.00 - -
Passive cotinine exposure 1.17 0.95, 1.46 .14 1.14 0.91, 1.42 .24 1.12 0.90, 1.40 .32
Active cotinine smoking 30.50 11.89, 78.24 < .001 22.21 8.55, 57.68 < .001 20.99 8.06, 54.67 < .001
Current (past 30 day) smoker at age 22 (n = 1345)
No cotinine exposure (reference) 1.00 - - 1.00 - - 1.00 - -
Passive cotinine exposure 1.23 0.92, 1.64 .17 1.19 0.88, 1.61 0.247 1.18 0.87, 1.59 .29
Active cotinine smoking 8.90 4.61, 17.20 < .001 7.20 3.64, 14.25 < .001 6.87 3.46, 13.66 < .001
OR = odds ratio; 95% CI = 95% confidence interval. Cotinine was treated as a categorical variable in these analyses so ORs reflect the odds of each smoking behaviour
for each cotinine level. Passive exposure is defined as levels exceeding 1 ng/ml up to 9 ng/ml in blood samples. Active smoking is defined as cotinine levels exceeding 10
ng/ml in blood samples. The basic model (model 1) was adjusted for age and sex. Model 2 was additionally adjusted for socioeconomic status, BMI and alcohol. Model 3
was additionally adjusted for passive smoke exposure (maternal smoking at 12 years).
�Cotinine levels indicating active smoking at 15 are not included in the table as they perfectly predicted whether young people had ever smoked at age 22.
https://doi.org/10.1371/journal.pone.0235629.t003
Table 4. Self-reported frequency of smoking at 16 and smoking status indicated by cotinine (ng/ml) level at 15 years (n = 1,194).
Cotinine indication Frequency of smoking
Never or not current Current less than daily Current daily Total
No exposure 311 (26%) 44 (4%) 6 (<1%) 361
Some exposure 661 (55%) 106 (9%) 30 (3%) 797
Indicated smoker 7 (<1%) 9 (<1%) 20 (2%) 36
Some exposure is defined as levels exceeding 1 ng/ml up to 9 ng/ml in blood samples. Indicated smoker is defined as cotinine levels exceeding 10 ng/ml in blood
samples.
https://doi.org/10.1371/journal.pone.0235629.t004
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reduced the sample size and therefore the power to detect an association, so seeing a consistent
residual association (albeit with weaker statistical evidence) is supportive of our interpretation
of the results.
Discussion
To our knowledge, this is the first longitudinal study of the association between cotinine in
adolescence and later e-cigarette use in early adulthood. Cotinine levels that are indicative of
active smoking at age 15 are strongly associated with increased odds of having ever used an e-
cigarette at age 22. Although the strength of evidence of this association was weakened after
adjustment for self-reported smoking behaviour at age 16 (assessed based on ever smoking sta-
tus, number of cigarettes smoked, active smoking and latent classes of smoking), some evi-
dence of association remained, indicating that some measurement error had occurred which
could potentially be due to misreporting.
The evidence provides further support (using biochemical verification) to research findings
suggesting that smoking is associated with later e-cigarette use. There was little evidence for an
association between cotinine levels indicative of passive exposure with later e-cigarette use.
This reflects previous research suggesting e-cigarette use is more common in smokers than
non-smokers [23, 24]. As causality cannot be inferred from associations, we cannot determine
whether smoking in adolescence causes future e-cigarette use. However, if there is a true causal
association the results provide some indication of the direction of causality due to the timing
of the data collection. When the data were collected (2006–2008), e-cigarettes were newly
available and in 2013 (over 5 years later when the first evidence of use among young people
Table 5. Associations of active smoking (determined by cotinine levels or self-report) at 15 years and ever use of e-cigarettes at 22 years (N = 1,194).
Model Active Smoking
Self-Report� Cotinine
OR 95% CI p-value OR 95% CI p-value
1 7.77 5.09, 11.85 < .001 10.47 4.88, 22.46 < .001
2 6.99 4.50, 10.86 < .001 8.06 3.69, 17.61 < .001
3 6.34 4.26, 10.34 < .001 7.24 3.29, 15.93 < .001
Self-report reference group = self-reported not current smoking; cotinine reference group = no exposure indicated by cotinine levels; OR = odds ratio; 95% CI = 95%
confidence interval. Cotinine was treated as a categorical variable in these analyses. Active exposure is defined as cotinine levels exceeding 10 ng/ml in blood samples; no
cotinine exposure is defined as cotinine levels of 0 ng/ml in blood samples. The basic model (model 1) was adjusted for age and sex. Model 2 was additionally adjusted
for socioeconomic status, BMI and alcohol. Model 3 was additionally adjusted for passive smoke exposure (maternal smoking at 12 years).
https://doi.org/10.1371/journal.pone.0235629.t005
Table 6. Associations of latent classes of transitions in smoking between 14 and 16 years and ever use of e-ciga-
rettes at 22 years (N = 1,194).
Latent classes of smoking OR 95% CI p-value
Never smokers (ref) 1 - -
Experimenters 4.13 2.29, 7.47 < .001
Late onset regular smokers 6.22 3.13, 12.36 < .001
Early onset regular smokers 0.92 0.11, 7.72 0.94
OR = odds ratio; 95% CI = 95% confidence interval. Latent classes of smoking transitions (early onset regular
smokers, late onset regular smokers, never smokers and experimenters) were categorised using data from
questionnaires at 14, 15 and 16 years. The model adjusted for age, sex, socioeconomic status, BMI and alcohol,
passive smoke exposure (maternal smoking at 12 years) and cotinine.
https://doi.org/10.1371/journal.pone.0235629.t006
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began to emerge) only 4.6% of 11–18 year olds had ever used e-cigarettes in Great Britain [25].
Therefore, it is very likely that these biomarker profiles reflect smoking behaviour in adoles-
cence without confounding from e-cigarette use, given that e-cigarettes were not widely used
among youths when the biomarker levels were measured.
If self-reported smoking and biomarker indications of smoking were both accurate and no
misreporting had occurred, the association between cotinine levels and later e-cigarette use
should have been fully attenuated when adjusting for self-reported smoking. The residual asso-
ciation indicates that smoking might be misreported in adolescence. Particularly, under-
reporting of smoking may be an issue when assessing self-reported smoke exposure; nearly
20% of the young people in this study who were identified as having cotinine levels indicating
active smoking reported not actively smoking. Previous research has also found that misre-
porting of smoking in young people is common [26]. There are many possible explanations
for misreporting when gathering self-report data on smoking behaviour from young people,
such as social pressures, fear of punishment or recall bias [27]. Therefore, research using self-
report data to explore the gateway hypothesis (that e-cigarettes act as a gateway to smoking)
may not be reliable as young people reporting to be ‘non-smokers’ who use e-cigarettes may
have previously smoked cigarettes.
Measurement error could also explain the residual association between smoking and later
e-cigarette use after adjusting for self-reported smoking. While there was an improvement in
the prediction of e-cigarette use when cotinine was included in the models with ever and active
smoking at age 16, there was less improvement when cotinine was added to models including
more detailed assessment of smoking intensity and duration. This suggests that in future stud-
ies, in the absence of biomarker verification when investigating the association between e-ciga-
rette use and smoking, more detailed self-report measures (e.g. transitions) should be used
rather than cruder measures (e.g. ever use) to avoid measurement error.
In addition, 36% of individuals identified as non-smokers by cotinine levels self-reported
being smokers. This discrepancy could have arisen from measurement error in cotinine (given
its short half-life [10], the measure may have been taken too early/late) or the cut-off used to
determine whether the young people’s cotinine levels were indicative of active smoking or not
may also have been too high. Despite 10 ng/mL frequently being used as the cut-off with high
sensitivity and specificity [28], some studies have used cut-offs from 1 ng/mL [29] up to 25 ng/
mL [30]. These discrepancies could be explained by changes in the young person’s smoking
status between the measures of self-reported smoking status and cotinine as they were mea-
sured between 0 and 29 months apart, with an average of 15 months. However, we adjusted
for the time between measures in sensitivity analyses that indicated that the remaining associa-
tion after adjusting for smoking status is unlikely to be due to the time gap between the mea-
sures. We also accounted for variability in smoking behaviour over time by assessing the latent
classes, which captured transition in smoking between age 14 and 16.
Focussing on this model (Model 4d), we found that early onset regular smoking was not
clearly associated with later e-cigarette use but experimentation and late onset regular smoking
was, even when cotinine was taken into account. This finding suggests an additional element
of smoking behaviour in predicting future e-cigarette use, which is not captured by cotinine
measures. In particular, results indicate that those individuals who have smoked for a longer
period of time (early onset smokers) are less likely to try e-cigarettes than experimenters and
late-onset smokers, and are no more likely to try e-cigarettes in the future than never smokers.
This highlights a difference between certain groups of the population in likelihood to engage
in e-cigarette use. Further research should explore this as those who start smoking earlier may
be more addicted to nicotine and may need more encouragement to quit whether that be by
using e-cigarettes or other methods.
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Implications of findings and limitations
Longitudinal studies exploring the gateway hypothesis often rely on self-reported smoking his-
tory to exclude those who have already been exposed to smoking at baseline (prior to e-ciga-
rette use) but it is also important to explore whether differences in biomarker levels that
indicate smoking are evident. Individuals who claim to have used e-cigarettes before smoking
cigarettes may be inaccurately reporting information and this misreporting could be captured
using biomarker verification. However, now that e-cigarettes are more popular and have been
shown to be a common correlate of cigarette smoking [31], replicating these results and avoid-
ing problems of reverse causation may prove difficult as e-cigarettes can contain nicotine and
therefore their use will increase cotinine levels.
The association between cotinine and e-cigarette use remained after including a range of
potential confounders in the model. However other sources of nicotine may be confounding
this association. Cannabis users in the UK often smoke cannabis with tobacco and may or may
not report this as smoking. When cannabis use was included in the model the association
between smoking and later e-cigarette use was somewhat attenuated. We did not include can-
nabis in the main analysis due to the potential for cannabis acting as an indicator of misreport-
ing rather than a confounder. The role of cannabis in the relationship between smoking and e-
cigarette use should be further explored. Another source of nicotine exposure which may not
have been fully captured in the model is passive smoking. Although we adjusted for maternal
smoking, the measure was assessed 3 years prior to the exposure and there are numerous other
sources through which the young person could have been passively exposed to smoke.
Ideally, we would have further explored the potential bias resulting from misreporting of
smoke exposure in studies exploring whether e-cigarettes act as a gateway to smoking by
restricting our analyses to those who claimed they were never smokers but were regular e-ciga-
rette users at 22 years. We were unable to do this due to the limited number of young people in
this study who fit those criteria. Only 1% of the sample had tried e-cigarettes but claimed to
have never smoked at 22 years and less than 1% of the sample were current e-cigarette users
and claimed to have never smoked a cigarette. The low number of non-smoking regular e-cig-
arette users is reflected in recent statistics from the England-based Smoking Toolkit Study [32]
and the literature exploring the gateway hypothesis (e.g. Primack and colleagues [33] identified
only 16 non-smoking ever e-cigarette users among 694 participants).
Conclusions
In summary, cotinine levels consistent with active smoking in adolescence are associated with
later e-cigarette use even after adjusting for some measures of self-reported smoking behav-
iour. This could have implications for studies assessing the gateway hypothesis that rely on
self-report measures of smoking behaviour. Future studies investigating prediction of e-ciga-
rette use should investigate use of more detailed self-report and objective measures.
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